Pharmaceuticals
Crystal Pharmatech's CDMO Business Unit - Crystal Formulation Services Received China Drug Product Manufacturing License, Achieving the Important Milestone in Formulation Capability
SUZHOU, China, April 19, 2023 /PRNewswire/ -- Crystal Formulation Services, a subsidiary of Crystal Pharmatech, has achieved an exciting new milestone in its formulation capabilities. The company was recently granted the "Drug Manufacturing License" (C Certificate) by the Jiangsu Medical Products...
2023-04-19 21:00
2959
China Jo-Jo Drugstores Announces the Termination of the Previously Proposed Registered Direct Offering
HANGZHOU, China, April 19, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, announced today that the...
2023-04-19 20:30
3692
Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use
- Subjects in Herniorrhaphy Study Dosed - Successful FDA Interactions on Two Pre-clinical Pipeline Products Also Discussed SAN DIEGO, April 18, 2023 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali" or "Cali Biosciences"), a biopharmaceutical company focused on the re...
2023-04-19 11:05
1993
AACR 2023 | ImmVira presented preclinical study results of first CAR-T enabler oncolytic product MVR-T7011 at AACR Annual Meeting
SHENZHEN, China, April 17, 2023 /PRNewswire/ -- On April 18, 2023, U.S. time,
ImmVira presented preclinical study results of CAR-T enabler oHSV product
MVR-7011 through poster publication at the American Association for Cancer
Research ("AACR") annual meeting.
2023-04-19 08:29
2370
Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting
* New preclinical data validate anti-tumor efficacy and intracranial activity of the drug candidate * Bridge submitted an IND application to the U.S. Food and Drug Administration in March, and expects to initiate the first-in-human study of BBT-207 this year SEONGNAM, South Korea and CAMBRIDG...
2023-04-19 07:00
2727
Technoderma Medicines Initiates TDM-105795 Androgenetic Alopecia Phase 2 Clinical Trial
CHENGDU, China, April 18, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has begun dosing patients in its Androgenetic Alopecia (AGA) Phase 2 clinical trial (NCT05802173) of topical TDM-105795 sol...
2023-04-18 21:00
2062
GC Genome to Present the Brand New Liquid Biopsy Platform for Cancer Detection at AACR Annual Meeting 2023
YONGIN, South Korea, April 18, 2023 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that the company will present data showcasing the deep learning algorithm that detects and classifies multi-cancer using methylation information and genomic data at the Americ...
2023-04-18 13:36
2192
GC Biopharma celebrates 'World Hemophilia Day'
* To display a large media façade on its Yong-in R&D Center YONGIN, South Korea, April 17, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, takes part in a campaign to celebrate World Hemophilia Day. The company announced that a l...
2023-04-18 09:03
2417
Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...
2023-04-18 08:00
3083
Promising Efficacy of AT101 CAR-T for Blood Cancer
SEOUL, South Korea, April 17, 2023 /PRNewswire/ -- AbClon, a South Korean biotech firm, presented non-clinical and phase 1 interim results of its AT101 novel CAR-T therapy at the annual 2023 AACR conference. AT101 targets the CD19 protein for treatment of blood cancer. AT101 demonstrated superio...
2023-04-18 02:00
2314
Asieris Releases 2022 Annual Report: Makes Steady Progress in its Clinical Development, Global Expansion to Treat Genitourinary Tumors, and Implementing its Commercialization Strategy to Provide Integrated Diagnosis-to-Treatment Solutions
SHANGHAI, April 17, 2023 /PRNewswire/ -- Asieris Pharmaceuticals(688176.SH), a global biopharma company specializing in the discovery, development and commercialization of innovative drugs that treat genitourinary (GU) tumors and other related diseases, today released its 2022 annual report. Whil...
2023-04-17 18:30
2705
Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development
TAIPEI, April 17, 2023 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announces today thatBassem Elmankabadi, M.D. joins Foresee as a Senior Vice President of Clinical Development. Dr. Bassem Elmankabadi is a Board Certified Surgeon with over 17 years of clinical backg...
2023-04-17 16:50
2853
Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, April 16, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...
2023-04-17 08:20
3893
Minghui Pharmaceutical Inc. Announces Phase 2 Clinical Trial Success of MH004 Cream as a Potential Best-in-Class Topical Treatment for Mild-to-Moderate Atopic Dermatitis and the FDA Clearance of its Global Phase 3 MRCT
* Study met both primary and all key secondary endpoints * Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score was -78.7% in 1.0% MH004 Cream-treated group compared to -46.7% in vehicle group * 79.6% individuals treated with 1.0% MH004 Cream achieved EASI-75 c...
2023-04-14 19:00
7347
Zenshine Pharmaceuticals' ZX-7101A Met the Primary Endpoint of the Phase 2 Study for the Treatment of Acute Uncomplicated Influenza in Adults
NANJING, China, April 13, 2023 /PRNewswire/ -- On April 1st, 2023, during the First Infection Collaboration Forum of the Chinese National Center for Infectious Diseases, Nanjing Zenshine Pharmaceuticals Co., Ltd. (Zenshine Pharmaceuticals) announced that its proprietary anti-influenza agent ZX-71...
2023-04-14 01:15
2806
Viva Biotech Attended SAPA-China
HONG KONG, April 12, 2023 /PRNewswire/ -- 6th-7th April, the "2022 SAPA-China Annual Conference - Opportunities and Challenges for the Development ofChina's Biopharmaceutical Industry" hosted by The Sino-American Pharmaceutical Professionals Association (SAPA) was held inChengdu, Sichuan. Viva Bi...
2023-04-13 11:33
2849
Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis
SEONGNAM, South Korea and CAMBRIDGE, Mass., April 12, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis, cancer, and inflammation, announced it has dosed the first patient in its Phase 2a clinical study...
2023-04-13 06:00
2917
Standigm announces Younsung Choo as chief executive officer
Former LG life Sciences exec and long-time Standigm advisor brings extensive
experience in pharmaceuticals and project management
SEOUL, South Korea, April 12, 2023 /PRNewswire/ -- Standigm
2023-04-13 00:07
2869
GC Genome-KAIST team Announces Publication of a Groundbreaking AI-Based Liquid Biopsy Technology for Multi-Cancer Early Detection and Localization in Nature Communications
YONGIN, South Korea, April 11, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagnostics company, today announced the publication of a new study inNature Communications, showcasing the company's novel AI-based liquid biopsy technology. The study highlights the unprecedented accura...
2023-04-12 11:06
2332
Specialised Therapeutics signs partnership agreement with Akeso Inc. and CTTQ-Akeso to commercialise new anti-PD1 antibody in Australia and Southeast Asia
SINGAPORE, April 11, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with CTTQ-Akeso ( Shanghai) Biomed. Tech. Co., Ltd. (CTTQ-Akeso)（jointly established by Akeso, Inc. (9926.HK, Akeso) and Chia Tai Tianqing Pharmaceutical Group Co...
2023-04-12 06:00
3380
Week's Top Stories
Most Reposted
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
[Picked up by 266 media titles]
2026-09-07 13:00
People See One Brand. The Internet May Show Them Hundreds More.
[Picked up by 264 media titles]
2026-09-07 09:00Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00Nuix Expands Generative AI for Legal Review, Debuts AI Chat for Case Data
[Picked up by 262 media titles]
2026-09-07 09:40Most Read
AIA Australia, Long Service Corporation, New Zealand Police and RMBL Investments Named 2026 Appian APJ Innovation Award Winners
2026-09-07 11:28
6539
